DK1427403T3 - Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling - Google Patents

Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling

Info

Publication number
DK1427403T3
DK1427403T3 DK02777129T DK02777129T DK1427403T3 DK 1427403 T3 DK1427403 T3 DK 1427403T3 DK 02777129 T DK02777129 T DK 02777129T DK 02777129 T DK02777129 T DK 02777129T DK 1427403 T3 DK1427403 T3 DK 1427403T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
combination
radiation
head
Prior art date
Application number
DK02777129T
Other languages
English (en)
Inventor
Bernd Groner
Bernd Hentsch
Peter A Herrlich
Pier Giuseppe Pelicci
Martin Goettlicher
Thorsten Heinzel
Winfried Stephan Wels
Saverio Minucci
Original Assignee
Topotarget Germany Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget Germany Ag filed Critical Topotarget Germany Ag
Application granted granted Critical
Publication of DK1427403T3 publication Critical patent/DK1427403T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02777129T 2001-09-18 2002-09-17 Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling DK1427403T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01121722A EP1293205A1 (en) 2001-09-18 2001-09-18 Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease

Publications (1)

Publication Number Publication Date
DK1427403T3 true DK1427403T3 (da) 2006-04-03

Family

ID=8178602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02777129T DK1427403T3 (da) 2001-09-18 2002-09-17 Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling

Country Status (11)

Country Link
US (1) US20050038113A1 (da)
EP (4) EP1293205A1 (da)
JP (1) JP2005512961A (da)
AT (1) ATE314063T1 (da)
AU (1) AU2002338716B2 (da)
CA (1) CA2460713A1 (da)
CY (1) CY1105552T1 (da)
DE (1) DE60208397T2 (da)
DK (1) DK1427403T3 (da)
ES (1) ES2252519T3 (da)
WO (1) WO2003024442A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
EP1628651A2 (en) * 2003-05-21 2006-03-01 Novartis AG Combination of histone deacetylase inhibitors with chemotherapeutic agents
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
CA2535889A1 (en) * 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP1824831A2 (en) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1855760A2 (en) 2005-02-03 2007-11-21 TopoTarget UK Limited Combination therapies using hdac inhibitors
US7869590B2 (en) * 2005-04-12 2011-01-11 Broadcom Corporation Method and system for hardware accelerator for implementing f9 integrity algorithm in WCDMA compliant handsets
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
NZ563236A (en) 2005-05-13 2010-12-24 Topotarget Uk Ltd Pharmaceutical formulations of N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, aka PXD-101, and arginine
JP2009501236A (ja) * 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8828392B2 (en) 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
AU2005339587B2 (en) * 2005-11-16 2011-11-03 Universidad Nacional Autonoma De Mexico Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
EP2012801A4 (en) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
DE102006022877B4 (de) 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER
CA2671649A1 (en) * 2006-12-06 2008-06-12 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
CN101801994A (zh) 2006-12-29 2010-08-11 格洛斯特制药公司 制备Romidepsin
US8110550B2 (en) * 2007-06-06 2012-02-07 University Of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
CA2700173C (en) 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
WO2010064422A1 (ja) * 2008-12-02 2010-06-10 静岡県公立大学法人 ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
KR101733189B1 (ko) * 2010-10-06 2017-05-08 (주)아모레퍼시픽 손톱 또는 발톱 성장 촉진용 조성물
PT2688572T (pt) 2011-03-21 2017-06-02 Valcuria Ab Composição farmacêutica com um inibidor de hdac e um esteroide e sua utilização
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
JP6551963B2 (ja) * 2014-05-14 2019-07-31 国立大学法人京都大学 巨核球前駆細胞の製造方法
MX2016016507A (es) 2014-06-12 2017-04-27 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
MX2024001104A (es) * 2021-07-27 2024-02-23 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
CA1339034C (en) * 1988-08-22 1997-04-01 Paul A. Tremblay Platinum complexes of single isomer neoalkyl acids
JPH0279969A (ja) * 1988-09-19 1990-03-20 Shigeyoshi Fujimoto 細胞障害性ｔ細胞誘導及び活性化の方法
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW248552B (da) * 1993-06-01 1995-06-01 Onoda Yakuhin Kogyo Kk
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US5672746A (en) * 1994-08-30 1997-09-30 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US6207147B1 (en) * 1996-10-11 2001-03-27 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
US6110970A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
AU2337601A (en) * 1999-12-23 2001-07-09 Ontario Cancer Institute, The Inhibition of gsk-3beta
EP1170008A1 (en) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors

Also Published As

Publication number Publication date
WO2003024442A3 (en) 2003-09-18
EP1602371A3 (en) 2006-11-15
CA2460713A1 (en) 2003-03-27
CY1105552T1 (el) 2010-07-28
ES2252519T3 (es) 2006-05-16
DE60208397D1 (de) 2006-02-02
JP2005512961A (ja) 2005-05-12
EP1602371A2 (en) 2005-12-07
WO2003024442A2 (en) 2003-03-27
DE60208397T2 (de) 2006-07-13
EP1529527A2 (en) 2005-05-11
EP1427403B1 (en) 2005-12-28
AU2002338716B2 (en) 2007-08-16
EP1529527A3 (en) 2005-05-25
EP1427403A2 (en) 2004-06-16
ATE314063T1 (de) 2006-01-15
EP1293205A1 (en) 2003-03-19
EP1427403B8 (en) 2006-03-22
US20050038113A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DK1427403T3 (da) Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
AR050713A1 (es) Uso de una neurotoxina botulinica para la preparacion de un medicamento para el tratamiento de un cancer
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
HRP20040944B1 (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
PT2111868E (pt) Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
DE60330914D1 (de) Arzneimittel mit shikonin als wirkstoff
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
ATE409039T1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
MXPA05010010A (es) Regimen de dosificacion de farmaco anti-inflamatorio no-esteroideo.
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
WO2004054497A3 (de) Verwendung einer trpm8 aktivierenden substanz zur tumorbehandlung
GT200600210A (es) Terapia genica de interferon-beta usdando un sistema mejorado de expresion regulada
UA88884C2 (ru) Набор для приготовления фармацевтических композиций цис-оксоплатина, фармацевтическая композиция и ее применение при лечении рака
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
IL153586A0 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
GR1004951B (el) Στοματοδιασπειρωμενα δισκια φλουοξετινης ΄η και αλατων αυτης
TH54155B (th) วิธีการรักษาอาการประสาทเสื่อม